Neuphoria Therapeutics Inc. (NEUP)

NASDAQ: NEUP · Real-Time Price · USD

4.150

-0.210 (-4.82%)

At close: Feb 27, 2026, 4:00 PM EST

4.300

+0.150 (3.61%)

After-hours: Feb 27, 2026, 5:57 PM EST

Revenue by Segment

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020	Jun '19 Jun 30, 2019	Jun '18 Jun 30, 2018	Jun '17 Jun 30, 2017	Jun '16 Jun 30, 2016
Drug Development	15.65M			4.17M	3.90M	2.07M	491.86K
Drug Development Growth	-			6.99%	88.75%	320.02%	-
Unallocated Rent Income	-			-	-	-	143.48K
Total	15.65M			4.17M	3.90M	2.07M	635.34K
Total Growth	-			6.99%	88.75%	225.17%	-78.28%

Revenue by Geography

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020	Jun '19 Jun 30, 2019	Jun '18 Jun 30, 2018	Jun '17 Jun 30, 2017	Jun '16 Jun 30, 2016
Australia	15.65M			4.17M	3.90M	2.07M	635.34K
Australia Growth	-			6.99%	88.75%	225.17%	-38.46%
Total	15.65M			4.17M	3.90M	2.07M	635.34K
Total Growth	-			6.99%	88.75%	225.17%	-78.28%

Source: S&P Global Market Intelligence.